Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Sulfadiazine

Generic name
Sulfadiazine
Brand name
ATC Code
J01EC02

Pharmacokinetics in children

No pharmacokinetic studies have been carried out in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Toxoplasmosis, congenital
Toxoplasmosis, postnatal
  • Oral
    • ≥ 2 months
      [4]
      • 100 - 150 mg/kg/day in 4 doses. Max: 8 g/day. In combination with pyrimethamine and folinic acid.
      • Duration of treatment:

        21 days; in immunosuppression up to 1-2 weeks after the symptoms disappear.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Dose adjustment not needed
GFR 30-50 ml/min/1.73 m2
Dose adjustment not needed
GFR 10-30 ml/min/1.73 m2
50 percentage of single dose and dosing interval : 6 uur
GFR < 10 ml/min/1.73 m2
A general recommendation is not provided
Clinical consequences

In renal impairment, renal excretion of sulfadiazine and the N-acetyl metabolite decreases. This increases the risk of side effects.

Patients on dialysis

No data are available on dose adjustment for dialysis.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Nausea, vomiting, diarrhoea, dizziness, tinnitus, crystalluria, hypersensitivity reaction and abnormal blood counts.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

Serious abnormalities in the blood count, hypersensitivity to sulphonamides.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Caution is needed with exposure of the skin to sunlight or UV radiation due to the risk of photosensitivity. Stop the administration immediately if skin-related symptoms appear. It is recommended that an adequate fluid intake should be maintained or the urine made alkaline to prevent crystalluria.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Trimethoprim and derivatives
J01EA01
Combinations of sulfonamides and trimethoprim, incl. derivatives
J01EE01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Schmidt DR, et al., Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine., Eur J Pediatr, 2006, 165, 19-25
  2. 20McLeod R et al. , Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study., Clin Infect Dis. , 2006, May 15;42(10), 1383-94
  3. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  4. Heyl, SmPC Sulfadiazin-Heyl® 500 mg Tabletten (6814197.00.00), 12/2016

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes